Long Position on AGN @ $175.00 on 11/30/2017 (Rumor)

Allergan plc (AGN) is a specialty pharmaceutical company.

The company develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments.

The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer’s disease.

It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices.

Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co.

Shares have sold off on concerns over a competing drug dubbed as "better Botox." Botox had an annual sales of $2.78 billion in 2016. Please see our blog about the stock and the competing drug. Higher share prices are expected for this stock.

52-Weeks Trading Range: $168.43 - $256.80

Entry Point: $175.00

Stop Loss: $166.25

Targt Price: $192.50

Updates

12/22/2017 2:58:58 PM

AGN closed at $165 after company lost court case on Combigan 

Position closed on 12/22/2017 at price of $165.00 with a -5.71% loss in 22 days.

Back to Portfolio